[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Genmab A/S ADR (GMAB)

Genmab A/S ADR (GMAB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 17,128,396
  • Shares Outstanding, K 623,531
  • Annual Sales, $ 3,720 M
  • Annual Income, $ 963,000 K
  • EBIT $ 1,242 M
  • EBITDA $ 1,313 M
  • 60-Month Beta 0.85
  • Price/Sales 4.36
  • Price/Cash Flow 16.17
  • Price/Book 2.86

Options Overview Details

View History
  • Implied Volatility 66.67% (+4.22%)
  • Historical Volatility 39.24%
  • IV Percentile 94%
  • IV Rank 64.01%
  • IV High 86.45% on 03/20/26
  • IV Low 31.49% on 08/28/25
  • Expected Move (DTE 15) 0.21 (0.77%)
  • Put/Call Vol Ratio 0.24
  • Today's Volume 622
  • Volume Avg (30-Day) 1,116
  • Put/Call OI Ratio 0.12
  • Today's Open Interest 64,940
  • Open Int (30-Day) 68,338
  • Expected Range 27.43 to 27.85

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 20 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $0.34
  • Number of Estimates 4
  • High Estimate $0.46
  • Low Estimate $0.25
  • Prior Year $0.54
  • Growth Rate Est. (year over year) -37.04%

Price Performance

See More
Period Period Low Period High Performance
1-Month
23.62 +17.02%
on 06/03/26
28.18 -1.92%
on 06/30/26
+2.19 (+8.61%)
since 06/01/26
3-Month
23.62 +17.02%
on 06/03/26
29.43 -6.08%
on 04/14/26
+0.42 (+1.54%)
since 04/01/26
52-Week
20.23 +36.66%
on 07/03/25
35.43 -21.99%
on 01/14/26
+6.90 (+33.27%)
since 07/01/25

Most Recent Stories

More News
Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival

Company Announcement Topline results from Phase 3 EPCORE ® DLBCL-4 evaluating epcoritamab in combination with lenalidomide...

GMAB : 27.64 (+0.62%)
Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Results from the Phase 2 EPCORE ® DLBCL-3 trial show fixed-duration epcoritamab monotherapy demonstrated early responses in elderly patients with newly diagnosed diffuse large B-cell...

GMAB : 27.64 (+0.62%)
Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Patients

Findings from a post-hoc subgroup analysis of the Phase 3 EPCORE ® FL-1 trial reinforce fixed-duration epcoritamab in combination with rituximab and lenalidomide (R 2...

GMAB : 27.64 (+0.62%)
Genmab to Highlight Advances Across Its Oncology Portfolio at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2026 Congress

Twenty-three abstracts will highlight the versatility and strength of Genmab’s portfolio and pipeline, including data from the comprehensive epcoritamab development program, including 4 oral presentations...

GMAB : 27.64 (+0.62%)
Genmab A/S Q1 Earnings Call Highlights

Genmab A/S (NASDAQ:GMAB) reported first-quarter 2026 results highlighting revenue growth, expanding proprietary product sales, and continued investment in its late-stage pipeline, while maintaining profitability....

GMAB : 27.64 (+0.62%)
Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian Cancer

Phase 1/2 RAINFOL™-01 data showed the combination of rinatabart sesutecan (Rina-S ® ) and bevacizumab was tolerable, with no new safety signals in...

GMAB : 27.64 (+0.62%)
Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Company Announcement Based on the topline results from the EPCORE ® DLBCL-1 trial, Genmab will engage global regulatory...

GMAB : 27.64 (+0.62%)
Genmab Partners with Anthropic to Accelerate Research and Development Through Agentic Artificial Intelligence

Supports Genmab’s ambition to build an AI-enabled innovation model that advances the company’s vision of bringing transformative antibody medicines to patients

GMAB : 27.64 (+0.62%)
Genmab Portfolio Prioritization Update

Company Announcement Genmab to discontinue clinical development of acasunlimab following a portfolio review ...

GMAB : 27.64 (+0.62%)
Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period

Company Announcement Transaction adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab’s portfolio ...

GMAB : 27.64 (+0.62%)
MRUS : 90.00 (-7.14%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Genmab A/S is a biotechnology company. It specializes in development of antibody therapeutics for the treatment of cancer. The company's product pipeline includes DARZALEX(R), Arzerra(R), tisotumab vedotin, enapotamab vedotin, HexaBody-DR5/DR5(R) and DuoBody-CD3xCD20 (R),which are in clinical stage....

See More

Key Turning Points

3rd Resistance Point 28.65
2nd Resistance Point 28.33
1st Resistance Point 27.98
Last Price 27.64
1st Support Level 27.31
2nd Support Level 26.99
3rd Support Level 26.64

See More

52-Week High 35.43
Fibonacci 61.8% 29.62
Fibonacci 50% 27.83
Last Price 27.64
Fibonacci 38.2% 26.03
52-Week Low 20.23

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.